Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Gap in H2S-NSAIDs literature
View:
Post by themagicbox on Jan 18, 2021 11:07am

Gap in H2S-NSAIDs literature

Has anyone, whos looked in depth in the H2S-NSAID literature by Wallace and others, found a gap in their literature? i.e. areas of for future research.
MUGS?
Comment by themagicbox on Jan 18, 2021 11:23am
and does anyone have a link to Wallace's "instrumental" paper that created the theory behind H2S promising application?
Comment by Thegoat81 on Jan 18, 2021 11:36am
https://www.researchgate.net/profile/John_Wallace11 Go nuts, let us know when you find the paper you're looking for as he has 623 publications. 
Comment by IrishCanuck on Jan 18, 2021 11:52am
There are no holes... Start with this Review and work your way back when you want a specific publication https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342563/
Comment by Inthepez on Jan 18, 2021 12:57pm
I would say gap in literature is on people with existing GI comorbidities, pregnant women, teenagers etc. Likely would get similar results, but gaps none the less. I’m sure that’ll be future areas of research. 
Comment by MrMugsy on Jan 18, 2021 2:10pm
Magicbox ... what kind of gap are you seeing w.r.t. future research? I think the company was planning on spending a lot of time on 340 after they got through 346 and 352.  Now ... I'm not so sure since there is a glimmer of hope that we're working on everything, even the IBD drugs, giving our potential partners valuable insight into the power of H2S. I think there's additional ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities